GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...

Clinical Trials

A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants

Phase 3

Completed

Conditions: Gastroenteritis

Interventions: Combination Product: HRV PCV-free
Combination Product: IPV

First Posted Date: 2024-03-26

Last Posted Date: 2024-10-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 400

Registration Number: NCT06331156

Locations: 🇨🇳
GSK Investigational Site, Yuechi-Guang'an, China

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Phase 2

Recruiting

Conditions: Carcinoma

Interventions: Biological: Dostarlimab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2024-03-19

Last Posted Date: 2024-05-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT06317311

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: GSK3915393

First Posted Date: 2024-03-19

Last Posted Date: 2024-12-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 150

Registration Number: NCT06317285

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

Phase 3

Recruiting

Conditions: Asthma

Interventions: Drug: Salbutamol HFA-152a
Drug: Salbutamol HFA-134a

First Posted Date: 2024-02-15

Last Posted Date: 2024-07-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 412

Registration Number: NCT06261957

Locations: 🇬🇧
GSK Investigational Site, Uttoxeter, United Kingdom

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Phase 3

Recruiting

Conditions: Neoplasms, Head and Neck

Interventions: Drug: Dostarlimab
Drug: Placebo

First Posted Date: 2024-02-13

Last Posted Date: 2024-07-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 864

Registration Number: NCT06256588

Locations: 🇬🇧
GSK Investigational Site, Wolverhampton, United Kingdom

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Phase 2

Recruiting

Conditions: Salmonella Infections

Interventions: Biological: iNTS-GMMA Dose C
Biological: MenACWY
Biological: Measles and Rubella vaccine
Biological: iNTS-GMMA Dose B
Biological: Yellow Fever vaccine
Drug: Placebo
Biological: iNTS-GMMA Dose A
Biological: Pentavalent vaccine
Combination Product: DTPa-HBV-IPV+Hib
Biological: Pneumococcal vaccine
Biological: Inactivated polio vaccine

First Posted Date: 2024-01-19

Last Posted Date: 2024-01-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 516

Registration Number: NCT06213506

Locations: 🇬🇭
GSK Investigational Site, Kumasi, Ghana

Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions

Phase 1

Completed

Conditions: Intestinal Diseases

Interventions: Drug: Albendazole IP 400 mg
Drug: Albendazole 400 mg

First Posted Date: 2024-01-11

Last Posted Date: 2024-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 70

Registration Number: NCT06201559

Locations: 🇮🇳
Lambda Therapeutic Research Ltd, Ahmedabad, Gujarat, India

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants

Phase 1

Not yet recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: GSK4347859
Drug: Placebo

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 44

Registration Number: NCT06188507

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

Phase 1

Recruiting

Conditions: Malaria, Falciparum

Interventions: Drug: GSK4024484C
Drug: Placebo

First Posted Date: 2023-12-14

Last Posted Date: 2024-02-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 144

Registration Number: NCT06171113

Locations: 🇬🇧
Clinical Unit Cambridge (Cuc)-Cambridge-United Kingdom-C, Cambridge, United Kingdom

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Phase 1

Terminated

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Belantamab Mafodotin
Drug: GSK3174998

First Posted Date: 2023-12-07

Last Posted Date: 2024-03-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 9

Registration Number: NCT06160609

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy